Valsartan, Losartan, and Irbesartan

The Valsartan docket consolidates claims over generic angiotensin-receptor-blocker blood-pressure medications contaminated with NDMA and NDEA — nitrosamine compounds classified as probable human carcinogens — alleging that patients who took the affected generics face an elevated risk of cancers including liver, stomach, and other gastrointestinal malignancies. With over fourteen hundred actions pending roughly seven years after centralization, this is a substantial, multi-manufacturer docket: because the contamination affected numerous generic manufacturers rather than a single branded product, claim evaluation often requires confirming which manufacturer's product a given plaintiff actually used, over what period, and at what dose.

That manufacturer-attribution question is often the first funding consideration in this docket, ahead of injury severity: two claimants with identical cancer diagnoses can have very different claim strength depending on whether pharmacy records clearly establish exposure to a contaminated lot from an identified defendant. Once attribution is established, valuation tracks familiar drug-injury variables — cancer type and staging, duration and dose of exposure, and the strength of the individualized causal record connecting that exposure to the specific diagnosis.

For a firm building inventory in this docket, portfolio-level financing is realistic once claims are grouped by manufacturer and exposure profile rather than treated as a single undifferentiated pool, since the underlying liability theories against different generic manufacturers are not identical. Medical-lien exposure is significant given the cancer diagnoses involved — oncology treatment, Medicare, and private-insurer liens should be sized early, since they can represent a substantial share of gross recovery in a cancer-injury claim. Criterica Capital's mass tort finance product, and medical-lien receivables financing where a firm is separately carrying lien-related exposure, are both structured for this kind of manufacturer-attributed drug-contamination claim.

A structural view of how manufacturer attribution shapes this litigation is available from Criterica Intelligence, and is a useful reference point before pricing claims against any single generic defendant.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.